search Created with Sketch.
search Created with Sketch.

Advertisement

dermwire-tv-logo Created with Sketch.
dermwire-tv-logo Created with Sketch.

Skin Cancer Perceptions, Cimzia for Psoriasis, Eczema and CV Risk

June 7, 2018

A new national survey, Skin Cancer In America 2018, conducted by Health Union, explores perceptions of patients with skin cancer. Cimzia (certolizumab pegol, UCB) has received FDA approval for treatment of adults with moderate to severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti TNF approved for psoriasis. There is now evidence that, like psoriasis and rosacea, eczema may be linked to cardiovascular risk. Spironolactone may be just as effective as antibiotics for the treatment of women with acne, researchers from the Perelman School of Medicine at the University of Pennsylvania report.

Advertisement

In This Series

View More

Advertisement